Diadema Partners’s Novo Nordisk NVO Stock Holding History

Diadema Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.81M	Buy	100,000 +85,423	+586%	+$3.67M	0.61%	45
2026 Q1	$521K	Buy	+14,577	New	+$691K	0.09%	107
2025 Q4	–	Sell	-25,000	Closed	-$1.28M	–	178
2025 Q3	$1.39M	Buy	+25,000	New	+$1.46M	0.35%	74
2025 Q2	–	Sell	-24,618	Closed	-$1.67M	–	119
2025 Q1	$1.68M	Buy	+24,618	New	+$2.03M	0.44%	49

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Diadema Partners's NVO Position: Q2 2026 in Review

Diadema Partners increased its Novo Nordisk (NVO) stake by 586% in Q2 2026, buying an estimated $3.67M and bringing the position to 100,000 shares worth $4.81M. The position accounts for 0.61% of the portfolio, ranked #45.

Diadema Partners first reported a position in NVO in Q1 2025 and has held it in 4 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Diadema Partners held 100,000 shares of Novo Nordisk worth $4.81M as of Q2 2026.
Diadema Partners bought 85,423 Novo Nordisk shares in Q2 2026, an estimated $3.67M.
Novo Nordisk made up 0.61% of Diadema Partners's portfolio in Q2 2026, its #45 holding.
Diadema Partners first reported a position in Novo Nordisk in Q1 2025 and has held it in 4 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.